Vascular Endothelial Growth Factor (VEGF) Inhibitor Market 2021 - Forecast To 2030

The Business Research Company’s Vascular Endothelial Growth Factor Inhibitor Market 2021 – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON , UK, November 30, 2021 /EINPresswire.com/ -- Companies in the vascular endothelial growth factor (VEGF) inhibitor market are focusing on combination therapy which reduces the likelihood of development in resistant cancer cells. Combination therapy uses different drugs with different effects, so that each drug can be used at its optimal dose, without intolerable side effects. Combination drug therapies are also useful for patients with advanced cancers that are not suitable for radiation therapy or surgical treatment. For instance, in November 2020, Switzerland-based pharmaceutical company, F. Hoffmann-La Roche AG announced that the European Commission (EC) had approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

TBRC’s holiday sale has begun with discounts on ALL market research reports! Grab your deal now.
https://www.thebusinessresearchcompany.com/global-market-reports

The global vascular endothelial growth factor inhibitor market size reached a value of nearly $30.31 billion in 2020, having increased at a compound annual growth rate (CAGR) of 7.8% since 2015. The VEGF inhibitor market is expected to grow from $30.31 billion in 2020 to $46.64 billion in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $63.38 billion in 2030.

North America was the largest region in the global vascular endothelial growth factor (VEGF) inhibitor market, accounting for 49.0% of the total in 2020. It was followed by Asia-Pacific, and then the other regions. Going forward, the fastest-growing regions in the vascular endothelial growth factor inhibitor market will be Eastern Europe, and, South America where growth will be at CAGRs of 14.6% and 13.1% respectively. These will be followed by Africa, and Middle East, where the markets are expected to grow at CAGRs of 12.2% and 12.0% respectively.

Read More On The Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitor-market

The increasing prevalence of cancer is a key factor driving the growth of the vascular endothelial growth factor inhibitor market. Cancer is considered the second leading cause of death globally, with around 1 in 6 deaths due to cancer. According to the American Cancer Society, there were a total of 1.8 million new cancer cases and 0.60 million deaths in the US in 2020, which is about 4,950 new cases and more than 1,600 deaths each day. About 70% of deaths from cancer occur in low- and middle-income countries. The International Agency for Research on Cancer estimates that by 2040, the number of new cancer cases per year will rise to 29.5 million and the number of cancer-related deaths will increase to 16.4 million worldwide. Therefore, the increasing prevalence of cancer is expected to drive the growth of the VEGF inhibitor market.

Major players covered in the global VEGF inhibitor industry are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals, Inc., Astrazeneca Plc., Novartis AG.

TBRC’s global VEGF inhibitor market report is segmented by drugs type into avastin, tecentriq, cometriq, eylea, others, by route of administration into oral, intravenous, by application into oncology, ophthalmology, others.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market 2021 - By Drug Type (Eylea, Avastin, Tagrisso, Tecentriq), By Route of Administration (Intravenous, Intravitreal, Oral), By Application (Oncology, Ophthalmology), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market overview, forecast vascular endothelial growth factor (VEGF) inhibitor market size and growth for the whole market, vascular endothelial growth factor (VEGF) inhibitor market segments, vascular endothelial growth factor (VEGF) inhibitor market analysis, vascular endothelial growth factor (VEGF) inhibitor market growth, vascular endothelial growth factor (VEGF) inhibitor market, vascular endothelial growth factor (VEGF) inhibitor market geographies, vascular endothelial growth factor (VEGF) inhibitor market trends, vascular endothelial growth factor (VEGF) inhibitor market overview, vascular endothelial growth factor (VEGF) inhibitor market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3949&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Protein Inhibitors Global Market Report 2021 - By Product (Protein Kinase Inhibitors, Monoclonal Antibody), By Application (Oncology, Inflammatory Diseases), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies), COVID-19 Growth And Change
https://www.thebusinessresearchcompany.com/report/protein-inhibitors-global-market-report-2020-30-covid-19-growth-and-change

Vascular Grafts Global Market Report 2021 - By Product (Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-Pass Graft), By Raw Material (Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts), By Application (Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure), By End-User (Hospitals, Ambulatory Surgical Centers), COVID-19 Growth And Change
https://www.thebusinessresearchcompany.com/report/vascular-grafts-global-market-report-2020-30-covid-19-growth-and-change

Oncology Biosimilars Global Market Report 2021 - By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Growth And Change
https://www.thebusinessresearchcompany.com/report/oncology-biosimilars-market-global-report

Interested to know more about The Business Research Company?

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Or get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn